Floatz logo

Rucaparib

Clear Cell Carcinoma

North Eastern German Society of Gynaecological OncologySmall moleculePhase 3Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Clear Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Dana-Farber Cancer Institute
Phase 2B
Lorigerlimab
MacroGenics
Phase 2CCC
Dostarlimab
Yonsei University
Phase 2CCC
Inno-206
Yonsei University
Phase 2CCC
NKT2152
NiKang Therapeutics, Inc.
Phase 1/2CCC

View all 20 →

Same molecule, other indications

Rucaparib is also rated in:

peritoneum cancerDormant
BB
Indicative ·
66 / 100
View asset →
Metastatic Castration Resistant Prostate CancerDormant
BB
Indicative ·
64 / 100
View asset →
ovarian cancerDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →